Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study

Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study

Background: The 21-gene Oncotype DX Breast Recurrence Score<sup>®</sup> assay is prognostic and predictive of chemotherapy benefit for patients with estrogen receptor-positive, HER2− early breast cancer (EBC). The KARMA Dx study evaluated the impact of the Recurrence Score<sup>®<...

Full description

Bibliographic Details
Main Authors: Antonio Llombart-Cussac, Antonio Anton-Torres, Beatriz Rojas, Raquel Andrés, Noelia Martinez, César A. Rodríguez, Sara Marin, Teresa Puértolas, Alejandro Falcón González, María Leonor Fernández-Murga, Carlos Hagen, Manuel Ruiz-Borrego
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Cancers
Subjects:
adjuvant
breast cancer
chemotherapy
clinical utility
Oncotype DX Breast Recurrence Score<sup>®</sup>
Recurrence Score<sup>®</sup> result
Online Access:https://www.mdpi.com/2072-6694/15/5/1529

Internet

https://www.mdpi.com/2072-6694/15/5/1529

Similar Items